Skip to main content
OpenTrials
Completed

NCT Number: NCT02769793

Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON

The purpose of this study is to determine whether levodopa/benserazide dispersible is effective in the adjunctive treatment of Parkinson's disease (PD) patients with delayed ON.

Completed

Looking for future studies?

Notify Me

Key information

Age range

31 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

SMG-SNU Boramae Medical Center, Seoul, South Korea

Loading trial locations.

About this study

Delayed ON is one of the motor complications of advanced PD patients that effect of anti-parkinsonian medication is delayed more than 40 minutes after intake. In the most severe cases, the effect does not appear even until next medication schedule, so called "No ON" status. It is important to manage delayed ON properly because it can interfere motor functions and quality of life of PD patients.

Levodopa/benserazide dispersible can be absorbed rapidly in the intestine, so theoretically it can break the poor response to conventional treatment of PD patients with delayed ON. However, this has not been proven by clinical trials till now.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients between 31 and 80 years
  • Parkinson disease (PD) was diagnosed by United Kingdom Parkinson disease brain bank criteria
  • Patients receiving stable Levodopa treatment at least 2 weeks prior to baseline visit
  • Delayed ON was confirmed by a specialized PD diary that records change in motor symptoms 90 minute after the first morning dose. Delayed ON is defined as delay of more than 40 minutes after the first morning dose for resolution of OFF state or experience of no ON state at least 1 per week.

Exclusion criteria

  • Existence of cognitive decline hard to participate in the clinical trial or K-Minimental Status Exam score 24 or less
  • Any contraindication of blood sampling
  • Subjects with clinically significant psychiatric illness
  • Subjects with a cancer or severe medical illness
  • Lactating, pregnant, or possible pregnant
  • History of malignant melanoma
  • Subjects with narrow-angle glaucoma
  • Subjects with hypersensitivity to levodopa or benserazide
  • Subjects treated with non-selective monoamine oxidase (MAO)-B inhibitors
  • Subjects with peptic ulcer, colitis, or gastrointestinal disease

Treatment and study plan

Levodopa dispersible

Drug

Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)

Other names: Madopar dispersible

levodopa

Drug

Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)

Other names: Madopar

Primary outcomes

  1. Change in the time to ON after first morning dose using 3-day PD diary

    Time frame: 4 weeks

    A specialized 3-day PD diary will be distributed to the patients 3 days prior to each visit. This diary will evaluate the latency of ON after intake of the study medication.

Secondary outcomes

  1. Change in the The Unified Parkinson Disease Rating Scale (UPDRS)

    Time frame: 4 weeks

    a scale for assessment of parkinsonian symptom severity in PD patients

  2. Change in the The Unified Dyskinesia Rating Scale (UDyskRS)

    Time frame: 4 weeks

    a scale for assessment of levodopa-induced dyskinesia in PD patients

  3. Change in the The Schwab & England Activity of daily living scale (SEADL)

    Time frame: 4 weeks

    a scale for activity of daily living assessment

  4. Change in the The Parkinson Disease Questionnaire-39 (PDQ-39)

    Time frame: 4 weeks

    a scale for health-related quality of life in PD patients

  5. Change in the Patient global improvement (PGI)

    Time frame: 4 weeks

    patient-centered assessment of global improvement

  6. Change in the Clinician global improvement (CGI)

    Time frame: 4 weeks

    clinician's assessment for global improvement

  7. Change in the K-Minimental status examination (K-MMSE)

    Time frame: 4 weeks

    global cognition assessment

  8. Change in the Total ON time, total OFF time using 3-day PD diary

    Time frame: 4 weeks

    a severity assessment index for PD patients with motor fluctuation

Other outcomes

  1. relationship between delayed ON and response to investigational drugs and the Helicobactor pylori serology and index for atrophic gastritis

    Time frame: at baseline and after 4 weeks of each treatment arm

    whether delayed ON and treatment response are affected by H.pylori status

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Collaborators

  • SMG-SNU Boramae Medical Center
  • Samsung Medical Center

Registry information

Official study title

Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
May 12, 2016
Registry last updated
May 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.